Vancomycin-Resistant Staphylococcus Aureus Infections Market
1 Introduction to Research & Analysis Reports
1.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Overall Market Size
2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size: 2021 VS 2028
2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players in Global Market
3.2 Top Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies Ranked by Revenue
3.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Companies
3.4 Top 3 and Top 5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies in Global Market, by Revenue in 2021
3.5 Global Companies Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Type
3.6 Tier 1, Tier 2 and Tier 3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players in Global Market
3.6.1 List of Global Tier 1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies
3.6.2 List of Global Tier 2 and Tier 3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Markets, 2021 & 2028
4.1.2 Injection
4.1.3 Pills
4.2 By Type - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue & Forecasts
4.2.1 By Type - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2022
4.2.2 By Type - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2023-2028
4.2.3 By Type - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue & Forecasts
5.2.1 By Application - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2022
5.2.2 By Application - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2023-2028
5.2.3 By Application - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2021 & 2028
6.2 By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue & Forecasts
6.2.1 By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2022
6.2.2 By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2023-2028
6.2.3 By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2028
6.3.2 US Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.3.3 Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.3.4 Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2028
6.4.2 Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4.3 France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4.4 U.K. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4.5 Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4.6 Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4.7 Nordic Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.4.8 Benelux Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2028
6.5.2 China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.5.3 Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.5.4 South Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.5.5 Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.5.6 India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2028
6.6.2 Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.6.3 Argentina Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2028
6.7.2 Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.7.3 Israel Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.7.4 Saudi Arabia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
6.7.5 UAE Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, 2017-2028
7 Players Profiles
7.1 Eli Lily
7.1.1 Eli Lily Corporate Summary
7.1.2 Eli Lily Business Overview
7.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.1.4 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.1.5 Eli Lily Key News
7.2 Wockhardt Ltd
7.2.1 Wockhardt Ltd Corporate Summary
7.2.2 Wockhardt Ltd Business Overview
7.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.2.4 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.2.5 Wockhardt Ltd Key News
7.3 Amprologix Ltd
7.3.1 Amprologix Ltd Corporate Summary
7.3.2 Amprologix Ltd Business Overview
7.3.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.3.4 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.3.5 Amprologix Ltd Key News
7.4 CrystalGenomics Inc
7.4.1 CrystalGenomics Inc Corporate Summary
7.4.2 CrystalGenomics Inc Business Overview
7.4.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.4.4 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.4.5 CrystalGenomics Inc Key News
7.5 Debiopharm International SA
7.5.1 Debiopharm International SA Corporate Summary
7.5.2 Debiopharm International SA Business Overview
7.5.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.5.4 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.5.5 Debiopharm International SA Key News
7.6 Destiny Pharma Plc
7.6.1 Destiny Pharma Plc Corporate Summary
7.6.2 Destiny Pharma Plc Business Overview
7.6.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.6.4 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.6.5 Destiny Pharma Plc Key News
7.7 Lysimmune BioScience
7.7.1 Lysimmune BioScience Corporate Summary
7.7.2 Lysimmune BioScience Business Overview
7.7.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.7.4 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.7.5 Lysimmune BioScience Key News
7.8 Roivant Sciences Ltd
7.8.1 Roivant Sciences Ltd Corporate Summary
7.8.2 Roivant Sciences Ltd Business Overview
7.8.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.8.4 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.8.5 Roivant Sciences Ltd Key News
7.9 TGV-Inhalonix Inc
7.9.1 TGV-Inhalonix Inc Corporate Summary
7.9.2 TGV-Inhalonix Inc Business Overview
7.9.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.9.4 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.9.5 TGV-Inhalonix Inc Key News
7.10 Therapeutic Systems Research Laboratories Inc
7.10.1 Therapeutic Systems Research Laboratories Inc Corporate Summary
7.10.2 Therapeutic Systems Research Laboratories Inc Business Overview
7.10.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Product Offerings
7.10.4 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global Market (2017-2022)
7.10.5 Therapeutic Systems Research Laboratories Inc Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Opportunities & Trends in Global Market
Table 2. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Drivers in Global Market
Table 3. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Restraints in Global Market
Table 4. Key Players of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in Global Market
Table 5. Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Companies, 2017-2022
Table 8. Global Companies Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Type
Table 9. List of Global Tier 1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2023-2028
Table 30. Eli Lily Corporate Summary
Table 31. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 32. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 33. Wockhardt Ltd Corporate Summary
Table 34. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 35. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 36. Amprologix Ltd Corporate Summary
Table 37. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 38. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 39. CrystalGenomics Inc Corporate Summary
Table 40. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 41. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 42. Debiopharm International SA Corporate Summary
Table 43. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 44. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 45. Destiny Pharma Plc Corporate Summary
Table 46. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 47. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 48. Lysimmune BioScience Corporate Summary
Table 49. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 50. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 51. Roivant Sciences Ltd Corporate Summary
Table 52. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 53. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 54. TGV-Inhalonix Inc Corporate Summary
Table 55. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 56. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
Table 57. Therapeutic Systems Research Laboratories Inc Corporate Summary
Table 58. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Offerings
Table 59. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Type in 2021
Figure 2. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Application in 2021
Figure 3. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in 2021
Figure 8. By Type - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 9. By Application - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 10. By Region - Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 11. By Country - North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 12. US Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 16. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 17. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 24. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 28. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 30. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share, 2017-2028
Figure 33. Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue, (US$, Mn), 2017-2028
Figure 37. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Industry Market Size
